相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma
Luke T. Nelson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
Nicholas J. Viney et al.
ESC HEART FAILURE (2021)
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
Dhruv S. Kazi et al.
CIRCULATION (2020)
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan et al.
DRUG RESISTANCE UPDATES (2020)
Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis
Graham Lohrmann et al.
JOURNAL OF CARDIAC FAILURE (2020)
Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
Suzanne Lentzsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tafamidis-A Pricey Therapy for a Not-So-Rare Condition
Jerry H. Gurwitz et al.
JAMA CARDIOLOGY (2020)
Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis
Jan M. Griffin et al.
CLINICAL TRANSPLANTATION (2020)
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation
Christopher D. Barrett et al.
JACC-HEART FAILURE (2020)
Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system
Jan M. Griffin et al.
CLINICAL TRANSPLANTATION (2020)
Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
Anita D'Souza et al.
ECLINICALMEDICINE (2020)
The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 x 20-mg Capsules in Healthy Volunteers
Peter A. Lockwood et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Glucocorticoids in multiple myeloma: past, present, and future
Nicholas Burwick et al.
ANNALS OF HEMATOLOGY (2019)
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma
Shumaila Muhammad Iqbal et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio
Eli Muchtar et al.
LEUKEMIA (2019)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils
Lorena Saelices et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
Daniel P. Judge et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
The proteostasis network and its decline in ageing
Mark S. Hipp et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
The pathology and changing epidemiology of dialysis-related cardiac beta-2 microglobulin amyloidosis
Allison D. Morris et al.
CARDIOVASCULAR PATHOLOGY (2019)
Stabilization of amyloidogenic immunoglobulin light chains by small molecules
Gareth J. Morgan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis
David Adams et al.
REVUE NEUROLOGIQUE (2019)
Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains
Pinaki Misra et al.
BIOCHEMISTRY (2019)
Transthyretin Amyloid Cardiomyopathy JACC State-of-the-Art Review
Frederick L. Ruberg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy
Richa Manwani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Rodney H. Falk et al.
BLOOD (2019)
Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies
Lingna Li et al.
BLOOD (2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
Richa Manwani et al.
BLOOD (2019)
Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis
Erin Karlstedt et al.
JOURNAL OF CARDIAC FAILURE (2019)
One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis
Camille V. Edwards et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era
Arnt V. Kristen et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition
Lorena Saelices et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
Jonathan D. Finn et al.
CELL REPORTS (2018)
Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis
Mark Miller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Venetoclax for the treatment of multiple myeloma
Iuliana Vaxman et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
H. Landau et al.
LEUKEMIA (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells
Esther Imperlini et al.
SCIENTIFIC REPORTS (2017)
AL amyloidosis: from molecular mechanisms to targeted therapies
Giampaolo Merlini
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Gregory P. Kaufman et al.
BLOOD (2017)
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala et al.
BLOOD (2017)
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis
Giovanni Palladini et al.
BLOOD (2017)
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Mathew S. Maurer et al.
CIRCULATION (2017)
Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases
Brandon T. Larsen et al.
HISTOPATHOLOGY (2016)
Structure of Monomeric Transthyretin Carrying the Clinically Important T119M Mutation
Jin Hae Kim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Effect of melphalan 140 mg/m2 vs 200 mg/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience
Lakshmikanth Katragadda et al.
CLINICAL TRANSPLANTATION (2016)
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
Niels W. C. J. van de Donk et al.
IMMUNOLOGICAL REVIEWS (2016)
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Morie A. Gertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The activities of amyloids from a structural perspective
Roland Riek et al.
NATURE (2016)
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
Ricardo Sant'Anna et al.
NATURE COMMUNICATIONS (2016)
Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage
Pallavi Manral et al.
BIOSCIENCE REPORTS (2015)
Uncovering the Mechanism of Aggregation of Human Transthyretin
Lorena Saelices et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Duncan B. Richards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Ole B. Suhr et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
Giovanni Palladini et al.
HAEMATOLOGICA (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients
G. Palladini et al.
LEUKEMIA (2014)
Age-Related Oxidative Modifications of Transthyretin Modulate Its Amyloidogenicity
Lei Zhao et al.
BIOCHEMISTRY (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Sravan C. Penchala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Amyloidosis in autoinflammatory syndromes
Laura Obici et al.
AUTOIMMUNITY REVIEWS (2012)
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44
Vittorio Perfetti et al.
BLOOD (2012)
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
Efstathios Kastritis et al.
BLOOD (2012)
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Angela Dispenzieri et al.
BLOOD (2012)
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
Shaji K. Kumar et al.
BLOOD (2012)
The Amyloid State of Proteins in Human Diseases
David Eisenberg et al.
CELL (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
B. C. Potts et al.
CURRENT CANCER DRUG TARGETS (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
Jonathan S. Wall et al.
BLOOD (2010)
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
Philippe Moreau et al.
BLOOD (2010)
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
Sascha Dietrich et al.
BLOOD (2010)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Karl Bodin et al.
NATURE (2010)
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway
Jianru Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Transthyretin: the servant of many masters
Joel N. Buxbaum et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition
Andreia Biolo et al.
CIRCULATION-HEART FAILURE (2008)
Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis
E. Ihse et al.
JOURNAL OF PATHOLOGY (2008)
Melphalan and its role in the management of patients with multiple myeloma
Patrizia Falco et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Giovanni Palladini et al.
BLOOD (2006)
Lenalidomide and thalidomide: Mechanisms of action - Similarities and differences
KC Anderson
SEMINARS IN HEMATOLOGY (2005)
Amyloid deposits in transthyretin-derived amyloidosis:: cleaved transthyretin is associated with distinct amyloid morphology
J Bergström et al.
JOURNAL OF PATHOLOGY (2005)
The biological and chemical basis for tissue-selective amyloid disease
Y Sekijima et al.
CELL (2005)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture
N Reixach et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628
MV Dhodapkar et al.
BLOOD (2004)
Molecular mechanisms of amyloidosis
G Merlini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prevention of transthyretin amyloid disease by changing protein misfolding energetics
P Hammarström et al.
SCIENCE (2003)
Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates
R Khurana et al.
BIOCHEMISTRY (2001)
Review: Immunoglobulin light chain amyloidosis - The archetype of structural and pathogenic variability
V Bellotti et al.
JOURNAL OF STRUCTURAL BIOLOGY (2000)
Immunoglobulin light chains, glycosaminoglycans, and amyloid
FJ Stevens et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
分享论文
